Bristol-Myers Squibb shares are trading higher after the company announced the FDA approved COBENFY for treatment of schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Bristol-Myers Squibb's shares rose following FDA approval of COBENFY for schizophrenia treatment.
September 27, 2024 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol-Myers Squibb's stock is trading higher due to FDA approval of their new drug, COBENFY, for schizophrenia treatment.
The FDA approval of COBENFY is a significant regulatory milestone for Bristol-Myers Squibb, likely boosting investor confidence and driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100